Amar Jesani, S Srinivasan, Sarojini N, Vaibhao Ambhore, Veena Johari | Economic and Political Weekly | Vol 50, Issue 14 | 4 April 2015
This article provides a detailed critique of the formulae to provide compensation to subjects of clinical trials who may suffer serious adverse effects during their participation. The present formulae used by the Central Drugs Standard Control Organization display a lack of medical ethics and disregard the accepted norms.
You may also want to refer to:
- Clinical Trial Related Injury: Note on formula to determine compensation
- Compensation for injury in drug trials in India
- Study on ‘Compensation for Clinical Trial Injuries: A comparative analysis of seven countries’
- National seminar on Access to Medicines and Compensation for Clinical Trial Injuries
- Compensation in Clinical Trials-A comparative analysis of seven countries
